
MDAI does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for MDAI and 80,000+ other tickers.
See exactly how MDAI's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MDAI and 80,000+ other tickers.
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. The company offers DeepView System, which uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye at the initial time point of wound presentation; and delivers a binary prediction on the wounds capacity to heal or not heal by a specified time point in the future to assist the physician in making a more accurate, timely, and informed decision regarding the treatment of the…

Spectral AI, Inc. (MDAI) Q2 2026 Earnings Call Transcript

Spectral AI NASDAQ: MDAI said its second-quarter results marked a transition toward commercial operations following the U.S. Food and Drug Administration's De Novo clearance of its DeepView System for burn assessment in May. The company reiterated its 2026 revenue guidance of approximately $18.5 million, which does not assume significant revenue from DeepView system sales.

Company Continues to Advance Towards First Commercial Sales of the DeepView® System for Burn Indication Strong Cash Position of $14.0 Million at June 30, 2026 DALLAS, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the second quarter ended June 30, 2026 (“Q2 2026”). “Spectral AI has entered the second half of 2026 with tremendous momentum and a clear sense of purpose,” said Vincent Capone, Chief Executive Officer of Spectral AI.

DALLAS, July 29, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the second quarter ended June 30, 2026 on Tuesday, August 11, 2026, after the close of the Nasdaq stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time on the same day to discuss its financial results.

Industry Veteran Brings Two Decades of Experience Driving Growth Through New Product Launches, Training and Education Industry Veteran Brings Two Decades of Experience Driving Growth Through New Product Launches, Training and Education